Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Metastasis | Research article

Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases

Authors: Nozomu Sakai, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Shigetsugu Takano, Masayuki Ohtsuka

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The relationship between KRAS mutational status and timing of colorectal liver metastasis (CRLM) remains unclear. This study evaluated the relationship between KRAS mutational status and long-term survival in patients with synchronous CRLM.

Methods

Of the 255 patients who underwent initial hepatic resection for CRLM between January 2001 and December 2018, the KRAS mutational status was examined in 101 patients. Medical records of these patients were reviewed to evaluate recurrence and survival outcomes.

Results

KRAS mutant status was identified in 38 patients (37.6%). The overall survival (OS) was significantly better in patients with wild-type KRAS than in those with mutant KRAS status. In patients with synchronous metastases, the OS of patients with wild-type KRAS was significantly better than those with mutant KRAS. Multivariate analyses indicated shorter OS to be independently associated with positive primary lymph node, and large tumor size and R1 resection in patients with metachronous metastasis, whereas to be independently associated with mutant KRAS status in patients with synchronous metastasis. Furthermore, in the subgroup of patients with synchronous metastases, the repeat resection rate for hepatic recurrence was significantly high in those with wild type KRAS than in those with mutant KRAS.

Conclusion

KRAS mutation is an independent prognostic factor in patients with synchronous CRLM, but not in patients with metachronous CRLM.

Zaydfudim VM, McMurry TL, Harrigan AM, Friel CM, Stukenborg GJ, Bauer TW, et al. Improving treatment and survival: a population-based study of current outcomes after a hepatic resection in patients with metastatic colorectal cancer. HPB (Oxford). 2015;17(11):1019–24. https://doi.org/10.1111/hpb.12488.CrossRefPubMedPubMedCentral

Engstrand J, Nilsson H, Stromberg C, Jonas E, Freedman J. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78. https://doi.org/10.1186/s12885-017-3925-x.CrossRefPubMedPubMedCentral

House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52, 52-5. https://doi.org/10.1016/j.jamcollsurg.2009.12.040.CrossRefPubMed

Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13(1):51–64. https://doi.org/10.1634/theoncologist.2007-0142.CrossRefPubMed

Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol. 2004;11(3):274–80. https://doi.org/10.1245/ASO.2004.03.085.CrossRefPubMed

Leung U, Gonen M, Allen PJ, Kingham TP, RP DM, Jarnagin WR, et al. Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection. Ann Surg. 2017;265(1):158–65. https://doi.org/10.1097/SLA.0000000000001624.

Sawada Y, Sahara K, Endo I, Sakamoto K, Honda G, Beppu T, et al. Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci. 2020;27(11):810–8. https://doi.org/10.1002/jhbp.810.CrossRefPubMed

Elias D, Cavalcanti A, Sabourin JC, Lassau N, Pignon JP, Ducreux M, et al. Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol. 1998;24(3):174–9. https://doi.org/10.1016/S0748-7983(98)92878-5.CrossRefPubMed

Adams RB, Langer B. Resection margins for colorectal metastases to the liver: do they make a difference? HPB Surg. 1996;9(2):115–7. https://doi.org/10.1155/1996/95180.CrossRefPubMedPubMedCentral

10.

Lordan JT, Karanjia ND. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases (Br J Surg 2007; 94: 1133-1138). Br J Surg. 2008;95(1):128–9; author reply 9. https://doi.org/10.1002/bjs.6124.CrossRefPubMed

11.

Muratore A, Ribero D, Zimmitti G, Mellano A, Langella S, Capussotti L. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol. 2010;17(5):1324–9. https://doi.org/10.1245/s10434-009-0770-4.CrossRefPubMed

12.

Liu W, Zhou JG, Sun Y, Zhang L, Xing BC. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis. Oncotarget. 2016;7(24):37277–87. https://doi.org/10.18632/oncotarget.8671.

13.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16. https://doi.org/10.1016/S0140-6736(08)60455-9.CrossRefPubMedPubMedCentral

14.

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. https://doi.org/10.1016/S1470-2045(09)70330-4.CrossRefPubMed

15.

Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, et al. European colorectal metastases treatment G, sixth international colorectal liver metastases W. combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–92. https://doi.org/10.1093/annonc/mdn735.CrossRefPubMed

16.

Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14(2):786–94. https://doi.org/10.1245/s10434-006-9215-5.CrossRefPubMed

17.

Kobayashi S, Beppu T, Honda G, Yamamoto M, Takahashi K, Endo I, et al. Survival benefit of and indications for adjuvant chemotherapy for resected colorectal liver metastases-a Japanese Nationwide survey. J Gastrointest Surg. 2020;24(6):1244–60. https://doi.org/10.1007/s11605-019-04250-9.CrossRefPubMed

18.

Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, et al. Adjuvant Oral uracil-Tegafur with Leucovorin for colorectal Cancer liver metastases: a randomized controlled trial. PLoS One. 2016;11(9):e0162400. https://doi.org/10.1371/journal.pone.0162400.CrossRefPubMedPubMedCentral

19.

Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17(2):572–8. https://doi.org/10.1245/s10434-009-0605-3.CrossRefPubMed

20.

Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119(23):4137–44. https://doi.org/10.1002/cncr.28347.CrossRefPubMedPubMedCentral

21.

Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26; discussion 26-7. https://doi.org/10.1097/SLA.0b013e3182a5025a.CrossRefPubMed

22.

Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136(1):83–90. https://doi.org/10.1002/ijc.28955.CrossRefPubMed

23.

Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112(12):1921–8. https://doi.org/10.1038/bjc.2015.142.CrossRefPubMedPubMedCentral

24.

Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015;112(4):720–8. https://doi.org/10.1038/bjc.2014.499.CrossRefPubMedPubMedCentral

25.

Takahashi M, Hasegawa K, Oba M, Aoki T, Sakamoto Y, Sugawara Y, et al. Repeat resection leads to long-term survival: analysis of 10-year follow-up of patients with colorectal liver metastases. Am J Surg. 2015;210(5):904–10. https://doi.org/10.1016/j.amjsurg.2015.01.026.CrossRefPubMed

26.

Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg. 1997;225(1):51–60 discussion −2.CrossRef

27.

Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, et al. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol. 2014;21(6):1817–24. https://doi.org/10.1245/s10434-014-3504-1.CrossRefPubMed

28.

Bellier J, De Wolf J, Hebbar M, Amrani ME, Desauw C, Leteurtre E, et al. Repeated resections of hepatic and pulmonary metastases from colorectal Cancer provide long-term survival. World J Surg. 2018;42(4):1171–9. https://doi.org/10.1007/s00268-017-4265-3.CrossRefPubMed

29.

Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(3):834–42. https://doi.org/10.1245/s10434-014-4042-6.CrossRefPubMed

30.

Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: a single institutional study. Cells. 2020;9(1):219. https://doi.org/10.3390/cells9010219.

31.

Margonis GA, Amini N, Andreatos N, Sasaki K, McVey J, Mirza MB, et al. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the international genetic consortium for liver metastases. HPB (Oxford). 2019;21(11):1527–34. https://doi.org/10.1016/j.hpb.2019.03.368.CrossRef

32.

33.

Margonis GA, Sasaki K, Andreatos N, Kim Y, Merath K, Wagner D, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2017;24(1):264–71. https://doi.org/10.1245/s10434-016-5609-1.CrossRefPubMed

34.

Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2016;23(8):2635–43. https://doi.org/10.1245/s10434-016-5187-2.CrossRefPubMedPubMedCentral

35.

Zhang Q, Peng J, Ye M, Weng W, Tan C, Ni S, et al. KRAS mutation predicted more Mirometastases and closer resection margins in patients with colorectal Cancer liver metastases. Ann Surg Oncol. 2020;27(4):1164–73. https://doi.org/10.1245/s10434-019-08065-5.CrossRefPubMed

36.

Nuzzo G, Giuliante F, Ardito F, Vellone M, Giovannini I, Federico B, et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery. 2008;143(3):384–93. https://doi.org/10.1016/j.surg.2007.09.038.CrossRefPubMed

37.

Xu D, Wang HW, Yan XL, Li J, Wang K, Xing BC. Sub-millimeter surgical margin is acceptable in patients with good tumor biology after liver resection for colorectal liver metastases. Eur J Surg Oncol. 2019;45(9):1551–8. https://doi.org/10.1016/j.ejso.2019.03.010.CrossRefPubMed

Title: Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases
Authors: Nozomu Sakai
Katsunori Furukawa
Tsukasa Takayashiki
Satoshi Kuboki
Shigetsugu Takano
Masayuki Ohtsuka
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08144-5

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Germline mutations in a clinic-based series of pregnancy associated breast cancer patients

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

pERK-mediated IL8 secretion can enhance the migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells

Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer

Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study